AxoGen, Inc (NASDAQ:AXGN) has earned a consensus recommendation of “Buy” from the seven research firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, four have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $23.25.
A number of research firms have recently issued reports on AXGN. BidaskClub lowered AxoGen from a “sell” rating to a “strong sell” rating in a report on Thursday, September 12th. Canaccord Genuity reduced their target price on AxoGen from $30.00 to $25.00 and set a “buy” rating for the company in a report on Thursday, November 7th. Cantor Fitzgerald reduced their target price on AxoGen from $21.00 to $19.00 and set an “overweight” rating for the company in a report on Thursday, November 7th. ValuEngine upgraded AxoGen from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 1st. Finally, William Blair lowered AxoGen from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 7th.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Parallel Advisors LLC increased its stake in shares of AxoGen by 9,583.9% in the third quarter. Parallel Advisors LLC now owns 3,002 shares of the medical equipment provider’s stock worth $37,000 after acquiring an additional 2,971 shares during the last quarter. Advisor Group Inc. increased its stake in shares of AxoGen by 86.3% in the second quarter. Advisor Group Inc. now owns 2,548 shares of the medical equipment provider’s stock worth $51,000 after acquiring an additional 1,180 shares during the last quarter. Stonebridge Capital Advisors LLC acquired a new position in shares of AxoGen in the second quarter worth $59,000. Synovus Financial Corp acquired a new position in shares of AxoGen in the third quarter worth $66,000. Finally, Aperio Group LLC acquired a new position in shares of AxoGen in the second quarter worth $77,000. Institutional investors own 81.27% of the company’s stock.
Shares of AXGN traded down $0.02 during mid-day trading on Thursday, reaching $15.59. The company’s stock had a trading volume of 300,100 shares, compared to its average volume of 545,502. The business has a fifty day moving average of $13.02 and a 200 day moving average of $17.11. The company has a market cap of $639.39 million, a price-to-earnings ratio of -28.87 and a beta of 0.14. AxoGen has a 1 year low of $10.91 and a 1 year high of $35.11. The company has a quick ratio of 7.38, a current ratio of 8.20 and a debt-to-equity ratio of 0.01.
AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Featured Story: Convertible Shares
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.